Recent studies have found that tumor mutation burden was related to the production of antitumor neoantigens and was identified as a useful biomarker to predict the response to immunotherapy, especially PD-L1 therapy (Chan et al., 2019). This evidence concerns the gene CD274 and neoplasm.